Karen W. Hoover

Karen W. Hoover

Auto-generated profile, based on publicly available information

Karen W. Hoover

Division of HIV Prevention, Centers for Disease Control and Prevention, Atlanta, GA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 September 2019 in Journal of Women's Health
Verified
Journal Article
Closed access
EBErin Bradley
Erin Bradley
KFKaitlin Forsberg
Kaitlin Forsberg
JBJoshua E. Betts
Joshua E. Betts
JDJulia B. DeLuca
Julia B. DeLuca
EKEmiko Kamitani
Emiko Kamitani
KHKaren W. Hoover
Karen W. Hoover
Oral HIV pre-exposure prophylaxis (PrEP) is a highly effective pill that HIV-negative individuals can take once daily to prevent HIV infection. Although PrEP is a private, user-controlled method that empowers women to protect themselves without relying on a partner's behavior, women's PrEP use has been extremely low. We systematically reviewed the literature to identify and summarize factors that may be affecting PrEP implementation for women in the United States. We conducted a search of the Centers for Disease Control and Prevention HIV/AIDS Prevention Research Synthesis Project database (MEDLINE, EMBASE, and CINAHL) and PubMed to identify peer-reviewed studies published between January 2000 and April 2018 that reported U.S. women's or health care providers' PrEP knowledge or awareness, willingness to use or prescribe, attitudes, barriers and facilitators to use or prescription, or PrEP adherence and discontinuation influences. Thirty-nine studies (26 women, 13 providers) met the eligibility criteria. In these studies, 0%–33% of women had heard of PrEP. Between 51% and 97% of women were willing to try PrEP, and 60%–92% of providers were willing to prescribe PrEP to women. Implementation barriers included access, cost, stigma, and medical distrust. Three studies addressed adherence or discontinuation. PrEP knowledge is low among women and providers. However, women and providers generally have positive views when aware of PrEP, including a willingness to use or prescribe PrEP to women. Most of the implementation barriers highlighted in studies were social or structural factors ( e.g ., access). Additional studies are needed to address research gaps, including studies of PrEP adherence and discontinuation.

2 December 2022 in MMWR. Morbidity and Mortality Weekly Report
Verified
Journal Article
Open access
KHKaren W. Hoover
Karen W. Hoover
WZWeiming Zhu
Weiming Zhu
ZGZanetta C. Gant
Zanetta C. Gant
KDKevin P. Delaney
Kevin P. Delaney
JWJeffrey Wiener
Jeffrey Wiener
AKAthena P. Kourtis
Athena P. Kourtis
This report describes HIV services and outcomes during the COVID-19 pandemic in the United States.

15 July 2014 in Maternal and Child Health Journal
Verified
Journal Article
Closed access
PDF file
LRLori de Ravello
Lori de Ravello
AFArianne Folkema
Arianne Folkema
STScott Tulloch
Scott Tulloch
MTMelanie Taylor
Melanie Taylor
BRBrigg Reilley
Brigg Reilley
ACAndreea Creanga
Andreea Creanga

1 September 2018 in Journal of Clinical Virology
Verified
Journal Article
Closed access
WZWeiming Zhu
Weiming Zhu
KMKimberly Mumby
Kimberly Mumby
DDDoreen Dankerlui
Doreen Dankerlui
JMJake Manteuffel
Jake Manteuffel
CHCal Ham
Cal Ham
KHKaren W. Hoover
Karen W. Hoover

1 January 2025 in JAIDS Journal of Acquired Immune Deficiency Syndromes
Verified
Journal Article
Closed access
YHYa-Lin A. Huang
Ya-Lin A. Huang
ELElliott Lowy
Elliott Lowy
WZWeiming Zhu
Weiming Zhu
LYLei Yu
Lei Yu
WWWei Wei
Wei Wei
LBLauren A. Md Beste
Lauren A. Md Beste
Objectives: It is important to monitor national HIV preexposure prophylaxis (PrEP) use in the United States. However, PrEP use data in the Veterans Health Administration (VHA) system are not included in the current monitoring surveillance. To address this gap, we examined the trends in PrEP use among U.S. Veterans receiving health services in the VHA system. Methods: We analyzed 2014–2022 VHA data to identify the annual number and prevalence of persons aged ≥18 years prescribed PrEP, stratified by sex, age, race/ethnicity, and region. We also assessed trends by calculating the estimated annual percent change and 95% confidence intervals using Poisson models. Results: The number of Veterans prescribed PrEP increased from 361 in 2014 to 6050 in 2022 with an estimated annual percent change of 29.6% (95% CI: 22.6 to 37.1). Of 6050 Veterans with PrEP prescriptions in 2022, 95.2% were men, 4.8% were women, 50.4% were White, 24.5% Black or African American (Black), and 14.0% Hispanic or Latino. The prevalence of Black and Hispanic or Latino individuals prescribed PrEP increased significantly from 2014 to 2022. Conclusions: VHA data fill a gap in monitoring PrEP use in the United States. We observed an increasing trend in the number of Veterans prescribed PrEP similar to trends among persons with commercial or public health insurance.

1 November 2026 in JAIDS Journal of Acquired Immune Deficiency Syndromes
Verified
Journal Article
Closed access
CCChristina Chandra
Christina Chandra
KMKevin M. Maloney
Kevin M. Maloney
AGAdrien Le Guillou
Adrien Le Guillou
KHKaren W. Hoover
Karen W. Hoover
SJSamuel M. Jenness
Samuel M. Jenness
Background: Event-driven preexposure prophylaxis (PrEP) (EDP), or PrEP taken around the time of sex, could be a preferred option over daily PrEP among cisgender gay, bisexual, and other men who have sex with men (MSM). However, recommendations for EDP versus daily dosing require consideration of optimal strategies for HIV prevention based on heterogeneous behavioral and biological PrEP indications. Methods: We used network-based mathematical HIV transmission modeling to understand the potential population-level impact of implementing EDP alongside daily PrEP using the 2-1-1 dosing schedule: 2 pills on the day of sex, 1 pill a day after, and 1 pill 2 days after. We simulated HIV transmission among 100,000 MSM in Atlanta, Georgia over 10 years. Compared with a baseline scenario with only daily PrEP and no EDP, we tested counterfactual scenarios that increased EDP use by changing initiation rates, expanding EDP to MSM not indicated for daily PrEP, and targeting EDP among MSM with low daily PrEP adherence who discontinued daily PrEP. Results: Increasing EDP initiation such that overall PrEP use was nearly double that at baseline (28.5% vs. 16.1%) yielded a percent of infections averted (PIA) of 18.3%. Expanding eligibility for EDP to any sexually active MSM resulted in a PIA of 15.8%. Targeting EDP for MSM discontinuing PrEP did not yield population-level improvements. Increasing initiation of EDP had a greater impact on PIA compared to improving EDP adherence. Conclusions: Using EDP to improve overall PrEP use resulted in reductions in HIV incidence, whereas targeted EDP initiation for MSM with low daily PrEP adherence did not improve outcomes over 10 years.